Solas BioVentures Announces the Addition of Scott Rader to its Team

 

JULY 15, 2020

​

​

​

 

 

 

 

 

​

​

​

​

​

​

​

​

​

​

​

 

Chattanooga, TN – Solas BioVentures today announced that Scott Rader has joined the company as Principal and Senior Vice President. His primary responsibilities will include investor relations, compliance, and corporate finance.

 

“I am excited to join the talented and experienced team at Solas BioVentures,” said Scott. “Dr. Adair and his partners have established an impressive track record with early-stage life science companies. I am honored to be a part of a group that is so dedicated to driving innovations that will improve patient lives and outcomes.”

 

Prior to joining Solas, Scott was SVP of Business Development for Argent Financial Group, a trust and specialty investment management group with over $25B in assets and offices across the Southern U.S. He will continue to be based out of Nashville, TN.

 

Dr. Dave Adair, the lead partner and co-founder of Solas, commented: “We are very honored to have another Go-Giver aboard the Solas Team. Scott shares our vision to provide value for patients, our portfolio companies, and our investors. His track record speaks volumes, and his heart and values eclipse any career accomplishments. He will be immediately accretive to our goal of building a sustainable and impactful biotech-focused management firm.”

Mark Hackett, a founding partner at Solas, says of Scott’s hire: “We are delighted to have Scott join the Solas team and look forward to a long and prosperous relationship. Scott brings tremendous experience in the areas of investor relations, business development, and compliance, which will serve Solas well as we strive to help companies bring life-changing technologies to market.”

​

 

​

ABOUT SOLAS BIOVENTURES:

 

Solas BioVentures invests exclusively in the Life Science industry, focusing primarily on early and development stage Biotech and Medtech companies. Solas is headquartered in Chattanooga, Tennessee, but our coverage is global. The Investment Team combines decades of medical, biotechnology, operational, managerial, legal, and financial experience. Solas maintains a founder- centric approach to foster breakthrough medicine and technology innovation.